Central Nervous System Drug Evaluation Using Positron Emission Tomography.
- Author:
Mizuho SEKINE
1
;
Jun MAEDA
;
Hitoshi SHIMADA
;
Tsuyoshi NOGAMI
;
Ryosuke ARAKAWA
;
Harumasa TAKANO
;
Makoto HIGUCHI
;
Hiroshi ITO
;
Yoshiro OKUBO
;
Tetsuya SUHARA
Author Information
1. Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan. sekine@nirs.go.jp
- Publication Type:In Vitro ; Review
- Keywords:
Positron emission tomography;
Occupancy;
Dopamine D2 receptor;
Serotonin transporter;
Norepinephrine transporter;
micro-PET
- MeSH:
Brain;
Central Nervous System;
Drug Evaluation;
Electrons;
Kinetics;
Mental Disorders;
Norepinephrine Plasma Membrane Transport Proteins;
Positron-Emission Tomography;
Receptors, Dopamine D2;
Serotonin Plasma Membrane Transport Proteins
- From:Clinical Psychopharmacology and Neuroscience
2011;9(1):9-16
- CountryRepublic of Korea
- Language:English
-
Abstract:
In conventional pharmacological research in the field of mental disorders, pharmacological effect and dose have been estimated by ethological approach and in vitro data of affinity to the site of action. In addition, the frequency of administration has been estimated from drug kinetics in blood. However, there is a problem regarding an objective index of drug effects in the living body. Furthermore, the possibility that the concentration of drug in blood does not necessarily reflect the drug kinetics in target organs has been pointed out. Positron emission tomography (PET) techniques have made progress for more than 20 years, and made it possible to measure the distribution and kinetics of small molecule components in living brain. In this article, we focused on rational drug dosing using receptor occupancy and proof-of-concept of drugs in the drug development process using PET.
